Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZSJRC)

Drug Name
8-acetyl-7-methoxy-2H-chromen-2-one Drug Info
Synonyms
8-Acetyl-7-methoxycoumarin; 8-acetyl-7-methoxy-2H-chromen-2-one; 89019-07-8; CHEMBL1288594; 8-Acetyl-7-methoxy-chromen-2-one; 2H-1-Benzopyran-2-one,8-acetyl-7-methoxy-; acetyl methoxycoumarin; ACMC-20lgfq; acetyl-7-methoxycoumarin, 8-; SCHEMBL16283617; CTK5G2445; DTXSID20556130; 8-acetyl-7-methoxy-2-oxochromene; 8-acetyl-7-methoxycoumarin ,98%; ZINC2562448; MFCD00270164; 8 - Acetyl - 7 - methoxycoumarin; BDBM50332024; 7-methoxy-8-coumarinul methyl ketone; AKOS016009510; RP27113; ST085908; AJ-40748; DB-078289; KB-200257; AX8111029
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
14116752
CAS Number
CAS 89019-07-8
TTD Drug ID
DMZSJRC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Carbonic anhydrase IX (CA-IX)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
PARABEN DMEW5Z8 N. A. N. A. Phase 3 [3]
PHENOL DM1QSM3 N. A. N. A. Phase 2/3 [2]
Coumate DMVKW0N Breast cancer 2C60-2C65 Phase 2 [4]
INDISULAM DM9SX6Y Lymphoma 2A80-2A86 Phase 2 [5]
Girentuximab I-124 DMG3O2Z Renal cell carcinoma 2C90 Phase 2 [6]
SULFAMIDE DMMAS3K N. A. N. A. Phase 1 [7]
BAY 79-4620 DM14XQN Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
90Y-cG250 DMJR6TC Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
FERULIC ACID DMJC7NF Discovery agent N.A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carbonic anhydrase IX (CA-IX) TT2LVK8 CAH9_HUMAN Inhibitor [1]

References

1 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8.
2 Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
3 Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
4 Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
5 Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
6 Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
7 Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
8 Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
9 Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.